Stemline Therapeutics Inc (STML.O) Quote| Reuters.com
Edition:
United States

Stemline Therapeutics Inc (STML.O)

STML.O on Consolidated Issue listed on NASDAQ Capital Market

6.83USD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$6.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

STML.O

Chart for STML.O

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: 0.41
Market Cap(Mil.): $124.74
Shares Outstanding(Mil.): 19.04
Dividend: --
Yield (%): --

Financials

  STML.O Industry Sector
P/E (TTM): -- 38.36 34.67
EPS (TTM): -2.20 -- --
ROI: -39.61 -6.77 14.11
ROE: -39.80 -6.10 15.33

BRIEF-Stemline Therapeutics reports Q1 loss per share $0.51

* Stemline Therapeutics reports first quarter 2016 financial results

May 09 2016

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,615 +5.00
Eisai Co., Ltd (4523.T) ¥5,934 +172.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,775 +31.00
Pfizer Inc. (PFE.N) $34.44 +0.64
Novartis AG (NOVN.S) CHF78.30 +0.85
Merck & Co., Inc. (MRK.N) $55.58 +0.27
Roche Holding Ltd. (ROG.S) CHF248.80 +2.60
Roche Holding Ltd. (RO.S) CHF253.00 +1.75
Sanofi SA (SASY.PA) €73.55 +0.73
GlaxoSmithKline plc (GSK.L) 1,532.00p +18.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.